EurekaMag.com logo
+ Site Statistics
References:
54,215,046
Abstracts:
30,230,908
PMIDs:
28,215,208
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

A phase II study of high-dose hydroxyurea and dacarbazine (DTIC) in the treatment of metastatic malignant melanoma



A phase II study of high-dose hydroxyurea and dacarbazine (DTIC) in the treatment of metastatic malignant melanoma



European Journal of Cancer 30A(7): 1027-1029



Dacarbazine (DTIC) exerts its major biochemical effect through the formation of methylated DNA adducts. Hydroxyurea (HU) is a ribonucleotide reductase inhibitor which blocks DNA excision-repair by the depiction of intracellular ribonucleotides. Combination of HU and DTIC was used to enhance the activity of DTIC by inhibiting DNA repair. 16 patients with metastatic malignant melanoma were treated with the combination. All patients had measurable disease and none had received prior systemic therapy. Hydroxyurea was given as a continuous intravenous (i.v.) infusion of 1 g/h (total 36 g) and DTIC 1 g/m-2 i.v. over 1 h, 23 h from the start of hydroxyurea infusion. 4 patients achieved partial remission with an objective remission rate of 25% (95% confidence interval (CI) 7-52%). Median duration of response was 3.5 months. 3 of the responding patients had predominant visceral metastases. Disease was stabilized in 5 patients with a median time to progression of 16 months. The predominant toxicity to this treatment was gastrointestinal, with 3 patients developing grade 3 nausea/vomiting. Only 1 patient developed grade 3 leucopenia complicated by septicaemia. It is concluded that the combination of hydroxyurea and DTIC is a well-tolerated regimen with activity against visceral metastases from malignant melanoma but the duration of response to this treatment is short.

(PDF emailed within 0-6 h: $19.90)

Accession: 008063372

Download citation: RISBibTeXText

PMID: 7946568

DOI: 10.1016/0959-8049(94)90137-6



Related references

Phase I/II study of imexon (AMP) plus dacarbazine (DTIC) in patients (Pts) with metastatic malignant melanoma. Journal of Clinical Oncology 26(15_suppl): 9066-9066, 2016

Pilot study of fotemustine ftmu dacarbazine dtic and vindesine vds in the treatment of metastatic malignant melanoma mmm. Proceedings of the American Association for Cancer Research Annual Meeting 32: 206, 1991

fotemustine (FM) and dacarbazine (DTIC) versus DTIC ± interferon α in advanced malignant melanoma: A phase III study of the Southern Italy Cooperative Oncology Group (SICOG). Journal of Clinical Oncology 24(18_suppl): Lba18000-Lba18000, 2016

Phase III randomized study of ipilimumab (IPI) plus dacarbazine (DTIC) versus DTIC alone as first-line treatment in patients with unresectable stage III or IV melanoma. Journal of Clinical Oncology 29(18_suppl): Lba5-Lba5, 2016

Phase II study of bleomycin, dacarbazine (DTIC) and vindesine in disseminated malignant melanoma. Journal of Cancer Research and Clinical Oncology 115(1): 93-95, 1989

Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Annals of Oncology 17(4): 563-570, 2006

The combination of recombinant interleukin 2 and dacarbazine dtic in metastatic malignant melanoma. Cancer Treatment Reviews 16(SUPPL A): 65-66, 1989

Durable responses and long-term progression-free survival observed in a phase II study of MDX-010 alone or in combination with dacarbazine (DTIC) in metastatic melanoma. Journal of Clinical Oncology 23(16_suppl): 7525-7525, 2016

A phase II study of dacarbazine, cisplatin, interferon-alpha and high-dose interleukin-2 in 'poor-risk' metastatic melanoma. European Journal of Cancer 32a(9): 1530-1533, 1996

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. Journal of Clinical Oncology 18(1): 158-166, 2000

Phase I trial of BAY 43-9006 (sorafenib) combined with dacarbazine (DTIC) in metastatic melanoma patients. Journal of Clinical Oncology 23(16_suppl): 7508-7508, 2016

Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazine. British Journal of Cancer 82(11): 1759-1763, 2000

Controlled study with imidazole carboxamide (DTIC), DTIC + bacillus Calmette-Guérin (BCG), and DTIC + corynebacterium parvum in advanced malignant melanoma. W.H.O. Collaborating Centres for Evaluation of Methods of Diagnosis and Treatment of Melanoma. Tumori 70(1): 41-48, 1984

DTIC vs. IFN-alpha plus DTIC in the treatment of patients with metastatic malignant melanoma. Neoplasma 43(2): 93-97, 1996